Neurocrine Biosciences uncommon illness drug presumably tied to issues of safety

Adam Feuerstein is a senior author and biotech columnist, reporting on the crossroads of drug improvement, enterprise, Wall Road, and biotechnology. He’s additionally a co-host of the weekly biotech podcast The Readout Loud and writer of the e-newsletter Adam’s Biotech Scorecard. You may attain Adam on Sign at stataf.54.

A gaggle of physicians and consultants in Prader-Willi syndrome, a uncommon illness that causes an insatiable need to eat, on Tuesday notified clinicians of a sequence of affected person deaths and instances of extreme negative effects probably related to Vykat XR, a newly accepted drug offered by Neurocrine Biosciences. 

Vykat was accepted by the Meals and Drug Administration in March 2025 to curb the extreme starvation sensation in youngsters and adults with Prader-Willi syndrome, or PWS. However since its clearance, seven individuals prescribed the drug have died, in keeping with the FDA’s Adversarial Occasion Monitoring System. Moreover, greater than 100 studies of great hostile occasions, largely instances of sufferers being hospitalized for swelling, respiratory, and coronary heart problems, have been reported to the FDA. 

“The intention of this assertion is to extend consciousness of the dangers for individuals with PWS when beginning Vykat XR,” the physicians and consultants wrote. Neither the deaths nor the extreme negative effects have been definitively linked to the drug, the group added.